Conduit Pharmaceuticals INC 8-K filings

Conduit Pharmaceuticals Inc. reports compliance with Nasdaq's Market Value of Publicly Held Securities and Equity standards as of March 31, 2025.

Conduit Pharmaceuticals receives an extension from Nasdaq to regain compliance with MVPHS and MVLS rules, while also achieving compliance with the Minimum Bid Price rule.

Conduit Pharmaceuticals is facing potential delisting from the Nasdaq Global Market due to non-compliance with market value requirements, despite efforts to reduce debt.

Conduit Pharmaceuticals Inc. announces the payoff of a $600,000 promissory note and the conversion of $1.7 million of a senior note into common stock, both aimed at reducing outstanding debt.

Conduit Pharmaceuticals has announced a 1-for-100 reverse stock split of its common stock, effective January 24, 2025, to increase its share price and maintain its Nasdaq listing.

Conduit Pharmaceuticals stockholders approved proposals related to the issuance of common stock upon the exercise of warrants and conversion of promissory notes at a special meeting held on January 13, 2025.

Conduit Pharmaceuticals is facing potential delisting from Nasdaq due to its low share price, and is planning a reverse stock split to regain compliance.

Conduit Pharmaceuticals has entered into an agreement with SARBORG Limited to leverage AI and cybernetics for optimizing drug development processes.

Conduit Pharmaceuticals has entered into a $5.7375 million convertible promissory note agreement with A.G.P./Alliance Global Partners and amended its existing debt agreement with Nirland Limited.

Conduit Pharmaceuticals has appointed Simon Fry as a new director and amended the employment agreement of James Bligh, the Interim CFO and Senior Vice President of Strategy.

Conduit Pharmaceuticals will restate its previously issued unaudited financial statements for the first two quarters of 2024 due to a reclassification of deferred commission payable.

Conduit Pharmaceuticals has entered into a bridge loan agreement for $600,000 and amended existing debt agreements to allow for potential conversion to common stock.

Conduit Pharmaceuticals has amended a convertible promissory note, extending the maturity date and issuing shares to settle outstanding obligations.

Conduit Pharmaceuticals has rescheduled its 2024 Annual Meeting of Stockholders from October 2nd to December 18th, with a new record date set for October 25th.

Conduit Pharmaceuticals has received notices from Nasdaq for failing to meet minimum market value requirements and has also discovered undisclosed share pledges by a director and a significant stockholder.

Conduit Pharmaceuticals has entered into an exclusive license agreement with AstraZeneca to develop and commercialize three clinical-stage assets, including two glucokinase activators and a myeloperoxidase inhibitor.

Conduit Pharmaceuticals has entered into a senior secured promissory note agreement for up to $2.65 million with Nirland Limited, including an original issue discount of $500,000.

Conduit Pharmaceuticals has amended its previous 8-K filing to clarify the record date for its 2024 annual meeting of stockholders, which is now set for August 12, 2024.

Conduit Pharmaceuticals has announced the date for its 2024 Annual Meeting of Stockholders and the deadlines for shareholder proposals and director nominations.

Conduit Pharmaceuticals received a notice from Nasdaq regarding non-compliance with independent audit committee requirements following a board member's resignation.

Conduit Pharmaceuticals will restate its unaudited financial statements for the first three quarters of 2023 due to an error in the accounting treatment of certain legal expenses.